IINN VS MYMD Stock Comparison

Performance

IINN
10/100

IINN returned -8.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

MYMD
10/100

MYMD returned -82.67% in the last 12 months. Based on SPY's performance of -12.16%, its performance is below average giving it a score of 10 of 100.

Sentiment

IINN
64/100

IINN had a bullish sentiment score of 63.94% across Twitter and StockTwits over the last 12 months. It had an average of 2.16 posts, 0.42 comments, and 2.10 likes per day.

MYMD

"Sentiment" not found for MYMD

Technicals

IINN
10/100

IINN receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

MYMD
25/100

MYMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

IINN
100/100

IINN has missed earnings 0 times in the last 20 quarters.

MYMD

"Earnings" not found for MYMD

Profit

IINN
21/100

Out of the last 18 quarters, IINN has had 3 profitable quarters and has increased their profits year over year on 3 of them.

MYMD
10/100

Out of the last 20 quarters, MYMD has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

IINN
40/100

IINN has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

MYMD
40/100

MYMD has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares Summary

Nasdaq / IINN

Healthcare

Medical - Devices

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.

MyMD Pharmaceuticals, Inc. Common Stock (DE) Summary

Nasdaq / MYMD

Healthcare

Biotechnology

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Power up your portfolio